Scimega Launches New Reverse Feasibility Resource Center to Attract the Best Oncology Compounds for Canadian Cancer Patients
Scimega Research is pleased to announce the launch of its new Reverse Feasibility Resource Center
Scimega Research, (
This microsite will enhance sponsor access to the program by providing regular updates that highlight Canada’s expertise in both early and late phase oncology trials. It currently features important information such as the number of oncology sites, key investigators, and catchment area size for each of the ten Canadian provinces.
Sponsors can sign up to receive free quarterly updates on the types of trials Scimega’s Reverse Feasibility Champions are looking to participate in. The Oncology Trial Needs Report for Canada will highlight the number of sites actively looking for trials, based on lines of treatment, tumor types and targets.
“The Reverse Feasibility Program was launched in 2009 to attract state-of-the-art clinical research to Canada,” said Denise Deakin, President & co-founder of Scimega Research. “It was founded on the premise that long-standing relationships between Scimega and top performing oncology sites could be leveraged by sponsors to maximize the performance and quality of their trials, while enhancing the overall clinical trial experience for both investigators and patients,” continued Ms. Deakin.
“Using this approach, we’ve seen as much as a 50% reduction is study start-up times, while meeting targeted patient recruitment objectives. It’s really
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Related Articles
- How the NIMBLE Study Supported Adherence With Quarterly Dosing of Cemdisiran
September 18th 2025
- Everything to Know About FDA’s Push Towards Radical Transparency in 2025
September 17th 2025